Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Public-Private Policy Dialogue Set for November 12
November 5, 2018
- LDP’s Eto Study Group Opposes 2-Stage Revision in 2019
November 2, 2018
- MHLW Asks 5 Prefectures to Cooperate in Distribution of MR Vaccines
November 2, 2018
- MHLW Panel to Discuss Changing Current Transitional Period for Pneumococcal Vaccinations in Elderly
November 2, 2018
- Chuikyo Leaning towards Drug Price Revision in October 2019 in Conjunction with Tax Hike
November 1, 2018
- Infection Specialist Proposes to Set Up Vaccination Council within Cabinet Office
October 31, 2018
- Daiichi Sankyo to Use MID-NET Database for Pralia PMS; Second Case from Private Sector
October 31, 2018
- MHLW Council to Discuss Otsuka’s Nalmefene for Treatment of Alcohol Dependency on Nov. 9
October 29, 2018
- ViiV’s HIV Med Juluca Up for MHLW Panel Review on Nov. 8
October 26, 2018
- MHLW to Map Out Additional Step against Rubella Outbreak by Year-End
October 25, 2018
- MHLW Warns against Advertising Claims Suggesting that OTC Cinnamon Bark Products Can Cure Diabetes
October 25, 2018
- AMED Selects 10 More Projects for CiCLE Grant Program, 4 for New Program to Support Startups
October 24, 2018
- MHLW Orders Label Revisions for Lamotrigine to Include Hemophagocytic Syndrome in ADR List
October 24, 2018
- 70% of Wholesalers Have Received Returns of “Opened and Resealed” Drugs: MHLW Survey
October 22, 2018
- MHLW Proposes New Approval Framework Incorporating Conditional OK, Sakigake Scheme
October 19, 2018
- Council Approves MHLW’s Plan to Deal with Difficult-to-Develop Drugs and Indications
October 19, 2018
- PMDA to Focus on Proper Use of Sakigake and Conditional Approval Systems in Its 4th Midterm Plan
October 19, 2018
- Council OKs Public Knowledge-Based Applications for Add’l Pediatric Indications for Blopress
October 19, 2018
- Chuikyo Wary on CEA Use for Reimbursement Decisions as MHLW Sorts Out Discussion Points towards Full Rollout
October 18, 2018
- 3 Pharma Groups Warn against Drug Price Cut in April 2019: Chuikyo
October 18, 2018
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…